Podoplanin expressing cancer-associated fibroblasts in oral cancer

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11345-11352

  Inoue, Harumi ^a   Tsuchiya, Hozumi ^a   Miyazaki, Yuji ^a   Kikuchi, Kentaro ^a   Ide, Fumio ^a   Sakashita, Hideaki ^a   Kusama, Kaoru ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Alpha smooth muscle actin ( SMA); Cancer associated fibroblast (CAF); Myofibroblast; Oral squamous cell carcinoma (OSCC); Podoplanin

Indexed keywords

MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FIBROBLAST; FOLLOW UP; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; SECONDARY; SQUAMOUS CELL CARCINOMA; STROMA CELL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FIBROBLASTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84927797727     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2450-7     Document Type: Article

References (48)

1. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, et al. T1 α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003;22:3546–56.
2. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993–6001.
3. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 2008;99:54–61.
4. Watanabe M, Okochi E, Sugimoto Y, Tsuruo T. Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res. 1988;48:6411–6.
5. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997;151:1141–52.
6. Williams MC, Cao Y, Hinds A, Rishi AK, Wetterwald A. T1 alpha protein is developmentally regulated and expressed by alveolar type I cells, choroid plexus, and ciliary epithelia of adult rats. Am J Respir Cell Mol Biol. 1996;14:577–85.
7. Oku Y, Tanaka A, González-Alva P, Sakashita H, Kusama K. Podoplanin expression in human pleomorphic adenomas. In: Varma AK, Qiu WL, editors. Oral oncology. Shanghai: Ocean Papers & Printers; 2008. p. 251–3.
8. Miyazaki Y, Okamoto E, Gonzalez-Alva P, Hayashi J, Ishige T, Kikuchi K, et al. The significance of podoplanin expression in human inflamed gingiva. J Oral Sci. 2009;51:283–7.
9. Sinzelle E, Duong Van Huyen JP, Breiteneder-Geleff S, Braunberger E, Deloche A, Kerjaschki D, et al. Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology. 2000;37:93–4.
10. Oe S, Hasegawa K, Nagase S, Kato R, Torii Y, Udagawa Y. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma. Int J Gynecol Pathol. 2010;29:405–10.
11. Sonne SB, Herlihy AS, Hoei-Hansen CE, Nielsen JE, Almstrup K, Skakkebaek NE, et al. Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch. 2006;449:200–6.
12. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006;111:483–8.
13. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385–94.
14. Durchdewald M, Guinea-Viniegra J, Haag D, Riehl A, Lichter P, Hahn M, et al. Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res. 2008;68:6877–83.
15. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913–21.
16. Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, Yamada A, et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci. 2009;100:2054–9.
17. Dumoff KL, Chu CS, Harris EE, Holtz D, Xu X, Zhang PJ, et al. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol. 2006;19:708–16.
18. Chuang WY, Yeh CJ, Wu YC, Chao YK, Liu YH, Tseng CK, et al. Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. Histol Histopathol. 2009;24:1021–7.
19. Rahadiani N, Ikeda J, Makino T, Tian T, Qiu Y, Mamat S, et al. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg Oncol. 2010;17:1311–23.
20. Rodrigo JP, Garcia-Carracedo D, Gonzalez MV, Mancebo G, Fresno MF, Garcia-Pedrero J. Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. Mol Cancer. 2010;9:48.
21. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006;107:563–9.
22. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008;26:354–60.
23. González-Alva P, Tanaka A, Oku Y, Miyazaki Y, Okamoto E, Fujinami M, et al. Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med. 2010;39:103–9.
24. Okamoto E, Kikuchi K, Miyazaki Y, Gonzalez-Alva P, Oku Y, Tanaka A, et al. Significance of podoplanin expression in keratocystic odontogenic tumor. J Oral Pathol Med. 2010;39:110–4.
25. Kikuchi K, Ito S, Inoue H, Gonzalez-Alva P, Miyazaki Y, Sakashita H, et al. Immunohistochemical expression of podoplanin in so-called hard alpha-keratin-expressing tumors, including calcifying cystic odontogenic tumor, craniopharyngioma, and pilomatrixoma. J Oral Sci. 2012;54:165–75.
26. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, et al. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol. 2012;33:183–94.
27. Meulmeester E, ten Dijke P. Integration of transcriptional signals at the tumor cell invasive front. Cell Cycle. 2010;9:2499–500.
28. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, et al. Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines. J Oral Sci. 2012;54:241–50.
29. Mbeunkui F, Johann Jr DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63:571–82.
30. Costea DE, Hills A, Osman AH, Thurlow J, Kalna G, Huang X, et al. Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res. 2013;73:3888–901.
31. Routray S, Sunkavali A, Bari K. Carcinoma-associated fibroblasts, its implication in head and neck squamous cell carcinoma: a mini review. Oral Dis. 2013. doi:10.1111/odi.12107.
32. Pula B, Witkiewicz W, Dziegiel P, Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. Int J Oncol. 2013;42:1849–57.
33. Neri S, Ishii G, Taira T, Hishida T, Yoshida J, Nishimura M, et al. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma. Ann Surg Oncol. 2012;19:3953–62.
34. Kitano H, Kageyama S, Hewitt SM, Hayashi R, Doki Y, Ozaki Y, et al. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch Pathol Lab Med. 2010;134:1520–7.
35. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer. 2008;123:1053–9.
36. Ono S, Ishii G, Nagai K, Takuwa T, Yoshida J, Nishimura M, et al. Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype. Chest. 2013;143:963–70.
37. Niemiec JA, Adamczyk A, Ambicka A, Mucha-Malecka A, W MW, Rys J. Triple-negative, basal marker-expressing, and high-grade breast carcinomas are characterized by high lymphatic vessel density and the expression of podoplanin in stromal fibroblasts. Appl Immunohistochem Mol Morphol. 2013; 22(1):10–6. doi:10.1097/PAI.0b013e318286030d.
38. Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat. 2012;134:237–44.
39. Schoppmann SF, Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G, et al. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis. 2013;30:441–6.
40. Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, et al. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology. 2009;77:53–62.
41. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–49.
42. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell. 2001;12:2730–41.
43. Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res. 1999;250:273–83.
44. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.
45. Allen M, Louise JJ. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 2011;223:162–76.
46. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170:1807–16.
47. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200:429–47.
48. Ito S, Ishii G, Hoshino A, Hashimoto H, Neri S, Kuwata T, et al. Tumor promoting effect of podoplanin-positive fibroblasts is mediated by enhanced RhoA activity. Biochem Biophys Res Commun. 2012;422:194–9.